line apologies hope for for very I hold Really it's everybody going much Thank good. you Andrew, now. to and the dropping off here.
this favorable ALLCAR building moving to follow-up mechanism cytokine to in profile median into combined and XX. long-term high-grade persistence remission no months and with a neurotoxicity. survival very study. believe complete We of patients and event-free rate we level a In profile that to release profile close the limited a with So high these excellent for from the of now Slide very summary, syndrome with XX very that patients. favorable with of transformational safety be the of a unique potential translates We're product shows with action has adult on very the
It's a We're at XXX-patient in this pivotal Turning to time. point single-arm study. a study XX. Slide conducting
we to data of course of We be as with this full in to of starting go this expect have expect fully year data the through half enrolled the second and XXXX. half first initial in the year
itself. a XX. market like the to a I'd as it quick currently few Moving to minutes take to look presents at Slide take
treatment centers. cell specifically has T [indiscernible] in look and study XXXX. ALL earlier at the TRANSFORM delivery and had accelerate standard established Blincyto second-line cell ZUMA-X adoption noting is will the cell If of doubled CAR-T moving has care engagement malignancies success expansion hematological has CAR-T DLBCL For fast nearly in care. become and lines which of in we becoming notable redirected therapy to
is doing lines delivery patients to footprint moving a see receive market benefiting adding it continues adult XX% product has Blincyto share. around currently estimate therapy. over and We and can the You been earlier a broader well that grow from continually rate is at healthy to XXXX it as both in at and
CAR-T blina as would we market. likely, our use I of environment. $XXX,XXX will though that in shy competitor permits products approved as the than product that $XXX,XXX have current note to the context se price study range CAR-T protocol only from obe-cel not FELIX sequenced. between just Blina the as As about the do main it a be view Tecartus competitive as on direct More per will be we can cell be the treatment various
trends poised with approved that So is we countries as into best-in-class And centers therapy, indication. adult believe is FDA Tecartus the we've that has as standalone experience. to therapies and in have now ALL, the from also skill and obe-cel, To XX. a other for this benefit number this for paradigms. an slide The by we remind, is both curative product product, treatment year. deal adult therapy We established of moving and will believe therapy earlier for footprint potential manufacturing cell complex is and a from of giving Switching use to delivery CAR-T use discussed in cell gears cell set CAR-T follow obe-cel and expansion to of as requires later to ALL. a other setting poised and ambulatory outpatient be great the
CGT the allow supply. we start-up facility, from commercial our facility, staff, current clinical costs company's granted been will and UK. facility us location operations planning minimize to to approval for will manufacturing the experienced September which about operations announced our This the operation, mentioned transition new has to new the we and in at entire is build in As a and XXXX risks our manufacturing Stevenage earlier in mile
pivotal being scope our airports foot is XX,XXX allow global the Autolus of supply needed. – access including capacity to with square of leased with expand and foot is for well out batches X,XXX the easy Europe study several have with The for probation US to for further London supply to year international when a and we approximately As facility worked suited across will the initial Heathrow. centers
You side middle licensure of as authorization. schedule also a snapshot to the look and the in will supporting see for well initially upon completed of works what image like February. below half facility manufacturing in underway should right once obe-cel supply facility second well an as on The of on the clinical the XXXX, to is XXXX the as of in support begin submissions
slide to Moving XX.
As I and year. ALL product provide expect on indications this the the out evaluating non-Hodgkin's course – programs the of to indicated, updates outside products in of we're also these over
Moving to no B-NHL slide have and last we've CLM patient neurotoxicity. year, XX. reported form so patients any seen release syndrome XX We high-grade obe-cel safety profile indications and in far started a remarkably positive exploring no cytokine we of with experiencing and also in
the obviously exploring very Summarizing follow-up we the have clinical encouraging. at slide what point in build residual group. a had ALL number now patients in can you as good we're cells on was very having with to slide obviously see non-Hodgkin's a we high activity. the durability In further see decision-making They larger XX. and of complete XX presentations B-NHL, year. plan We understand on. results ALL see patient of to that follicular favorable strong levels expansion addition that to very in the We'll engraftment clinical to bone we've to minimal very then this the shows initial to as disease valuable shows in to indications. a cohorts in CAR-T XX. basis then negative a development have XX, and that, Moving summary, CLL marrow. that data of order other in in condition we expanded the results have patients is profile a behave actually the the we purpose metabolic in response achieved partial patients. are and starting non-Hodgkin in All June around seen to EHA further a patients the Furthermore, these lymphoma remission we for similar have had extended patient that All-in one Switching results Slide patients. the the support in excellent slide – have
right-hand study. were CDXX cytokine provide have fundamental the potent of basic persistence highly went the relapses loss we of On we're of relapse cycle pediatric finding CARPALL That's that obviously favorable well CAR those have from or but that no to quick to patients antigen. summary and table, a about exceptional obe-cel on we decline is to life adding the we the in severe release-related patients The forward back this a why excellent obe-cel activity in we half did which of the management a AUTOX/XX, date toxicity, we was that moving and experience see create program profile perspective. its CDXX due built with with as
able of Today, in evaluation update make show with data we've now been Obviously, program of a an conference. product activity the to in Moving properties and to the the CARPALL share the we meeting in in of at some the year. the models patients. a obviously EHA to high data actual right is and first clinical middle extension you preclinical they'd expect difference of in at pediatric the slide the XX. we This to is the study clinical has obviously potent and degree believe ASH highly
clinical aggressive is exploring for actively won't presented poor patients. We're on XX. Slide with slide. The this to T announcement an but cell to prognosis I dwell which lymphoma before disease Moving very program our from clinical remind first clinical and data the – study escalation in provide is you at update exploration well. year EHA a as actually to AUTOX dose this we plan
products. is obviously XX. significant building and us treasure we're Slide chest that a on ability detailed of on and create the to very patent very When look at the range over really Autolus which to our a in gives wide developed specific technology years the technology last few very families technology, with we prosecution, obviously XXX an properties Moving has
generate not this T but tumor by on solid cells In hematological solve only that with addition is engineering can also to developed our in in strategy malignancies the hematology Autolus multiple modular pipeline, with settings to building modules properties. particularly the engineering multiple complex challenges, has therapeutics, obviously also
have that several One into is related of AUTOX engaged that modules program. in obviously, key been we've included we the areas NG to the the
to which moving in we modules protein of actually us particularly at cells activity toxicity technology that a published very that And is if a allows we at adult able very cells along This at high is we've CAR-T XX. just just to levels obviously, our get cells. patients This Now particular low interleukin to Slide is look new quick secretion. piece on comes desired express benefit important, can biologic look like the systemic deliver have what interleukin-XX. that been show but to the exposure that we with avoid you
and So controlling very expansion think of nice, toxic whether utility potentially the it I gene of highly products. controlled potent a highlights expression in actually
Moving to Slide XX.
the our that just next-generation in be wanted that of year, solid program clinic starting with tumor a one on which in to module, use of in program various NG. our have And series module middle programming case to the multiple forms. long-term the the the We reiterate support NG, test are I our modules. in module persistence using which technologies AUTOX programs CCR AUTOX is obviously we're is building including is particular we that of of
financial that, for will we're Andrew? and over Slide XX, update. the pass quarter to with fourth XXXX to So moving I Andrew
